News
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production
15 Mar 24
Biotech, Large Cap, News, Health Care, General
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
14 Mar 24
News, Short Ideas, Pre-Market Outlook, Markets, Trading Ideas
CymaBay Announces European Medicines Agency Accepts For Review The Marketing Authorization Application For Seladelpar For The Treatment Of Primary Biliary Cholangitis
4 Mar 24
Biotech, News, Eurozone, Markets, General
HC Wainwright & Co. Reiterates Neutral on CymaBay Therapeutics, Maintains $32.5 Price Target
29 Feb 24
News, Price Target, Reiteration, Analyst Ratings
CymaBay Therapeutics Q4 EPS $(0.35) Misses $(0.31) Estimate
28 Feb 24
Earnings, News
Leerink Partners Downgrades CymaBay Therapeutics to Market Perform, Announces $32.5 Price Target
20 Feb 24
News, Downgrades, Price Target, Analyst Ratings
LifeSci Capital Downgrades CymaBay Therapeutics to Market Perform
14 Feb 24
News, Downgrades, Analyst Ratings
Piper Sandler Downgrades CymaBay Therapeutics to Neutral, Lowers Price Target to $32.5
14 Feb 24
News, Downgrades, Price Target, Analyst Ratings
CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst
13 Feb 24
Analyst Color, Biotech, Equities, Large Cap, M&A, News, Health Care, Price Target, Reiteration, Analyst Ratings, Trading Ideas, General
BTIG Downgrades CymaBay Therapeutics to Neutral
13 Feb 24
News, Downgrades, Analyst Ratings
HC Wainwright & Co. Downgrades CymaBay Therapeutics to Neutral
13 Feb 24
News, Downgrades, Analyst Ratings
Cantor Fitzgerald Downgrades CymaBay Therapeutics to Neutral, Announces $32.5 Price Target
13 Feb 24
News, Downgrades, Price Target, Analyst Ratings
JonesTrading Downgrades CymaBay Therapeutics to Hold
13 Feb 24
News, Downgrades, Analyst Ratings
Fear & Greed Index Remains In 'Extreme Greed' Zone Ahead Of Inflation Data; Dow Hits Record High
13 Feb 24
Earnings, News, Pre-Market Outlook, Markets, Trading Ideas
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
12 Feb 24
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets, Trading Ideas
William Blair Downgrades CymaBay Therapeutics to Market Perform
12 Feb 24
News, Downgrades, Analyst Ratings
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
12 Feb 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Health Care Company Gilead Sciences Announces Acquisition of CymaBay Therapeutics
12 Feb 24
M&A, News, Trading Ideas, General
Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B
12 Feb 24
Biotech, Equities, Large Cap, M&A, News, Health Care, Movers, Trading Ideas, General
Gilead Sciences Expands Liver Portfolio With Acquisition Of CymaBay Therapeutics For $32.50/Share Or A Total Equity Value Of $4.3B
12 Feb 24
M&A
Press releases
Gilead Sciences Announces Completion of Acquisition of CymaBay
22 Mar 24
Press Releases
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CBAY, SCTL, EVRI
29 Feb 24
Press Releases
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
28 Feb 24
Earnings, Press Releases
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CBAY, IONM, WISH, FREE
24 Feb 24
Press Releases
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
21 Feb 24
Press Releases
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates DOOR, ZFOX, CBAY, WISH
17 Feb 24
Press Releases
CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY
16 Feb 24
Press Releases
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FANG, CBAY, WISH
12 Feb 24
News, Legal, Press Releases
Kuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law Firm
12 Feb 24
Press Releases
INVESTIGATION ALERT: Halper Sadeh LLC Investigates FANG, WISH, CBAY
12 Feb 24
Press Releases
Shareholder Alert: Ademi LLP investigates whether CymaBay Therapeutics, Inc. has obtained a Fair Price in its transaction with Gilead
12 Feb 24
Press Releases
CBAY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CymaBay Therapeutics, Inc. Is Fair to Shareholders
12 Feb 24
Press Releases
CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
12 Feb 24
Press Releases
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
12 Feb 24
Press Releases